Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (361-370 of 713) with videos related to

Pageof 72
Sort By:
Blood|October 24, 2002
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cancer|July 2, 2003
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implicationsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Blood|July 5, 2017
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuationKate J Newberry, Keyur Patel, Lucia Masarova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Pregnancy among patients with chronic myeloid leukemia treated with imatinibPatricia Ault, Hagop Kantarjian, Susan O'Brien, et al.
Blood|April 8, 2006
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failureElias Jabbour, Jorge Cortes, Hagop M Kantarjian, et al.
Cancer|November 30, 2006
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcomeHagop M Kantarjian, Susan O'Brien, Jianqin Shan, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 2, 2014
Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentationCourtney D DiNardo, Guilin Tang, Naveen Pemmaraju, et al.
Cancer|June 25, 2005
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndromeElias Jabbour, Srdan Verstovsek, Francis Giles, et al.
Cancer|June 23, 2005
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapyHagop M Kantarjian, Carlos E Bueso-Ramos, Moshe Talpaz, et al.
Journal of the National Cancer Institute|January 31, 2008
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemiaWeiguo Zhang, Marina Konopleva, Yue-xi Shi, et al.
Pageof 72

Showing results (361-370 of 713) with videos related to

Sort By:
Pageof 72
Blood|October 24, 2002
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cancer|July 2, 2003
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implicationsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Blood|July 5, 2017
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuationKate J Newberry, Keyur Patel, Lucia Masarova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Pregnancy among patients with chronic myeloid leukemia treated with imatinibPatricia Ault, Hagop Kantarjian, Susan O'Brien, et al.
Blood|April 8, 2006
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failureElias Jabbour, Jorge Cortes, Hagop M Kantarjian, et al.
Cancer|November 30, 2006
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcomeHagop M Kantarjian, Susan O'Brien, Jianqin Shan, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 2, 2014
Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentationCourtney D DiNardo, Guilin Tang, Naveen Pemmaraju, et al.
Cancer|June 25, 2005
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndromeElias Jabbour, Srdan Verstovsek, Francis Giles, et al.
Cancer|June 23, 2005
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapyHagop M Kantarjian, Carlos E Bueso-Ramos, Moshe Talpaz, et al.
Journal of the National Cancer Institute|January 31, 2008
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemiaWeiguo Zhang, Marina Konopleva, Yue-xi Shi, et al.
Pageof 72